Advanced Endometrial Cancer Study GOG-0258

Advanced Endometrial Cancer Study GOG-0258

Share this:

PROTOCOL ID

GOG 0258

PROTOCOL DESCRIPTION

A randomized phase III trial of cisplatin and tumor volume directed irradiation by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced, endometrial carcinoma: GOG-0258

DESCRIPTION

This study will compare the effects of two treatments in patients with endometrial cancer contained in the abdomen as well as collect samples of your tumor tissue and blood to help create special tests to determine which patients may respond to and have a better prognosis to certain treatments. The investigational treatment consists of Cisplatin given together with radiation therapy followed by the drugs Carboplatin and Paclitaxel for four cycles. Another treatment, which is the current standard therapy, consists of Carboplatin and Paclitaxel given for six cycles without radiation therapy.

The participant and/or their insurance provider will be responsible for the costs of medical care given while in the study.

ELIGIBILITY CRITERIA

In general, this study is looking for participants who:

  • Have stage III or IVA endometrial cancer OR stage I and II clear cell of serous papillary uterine cancer with positive cytology.

Primary Investigator(s):

Janet Osborne, M.D.

Contact Information

Vickie Yates, Research Nurse Coordinator
Carilion GYN Oncology
540-204-7635
vlyates@carilionclinic.org